These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 23663372)
41. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504 [TBL] [Abstract][Full Text] [Related]
42. Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis. Rejdak K; Leary SM; Petzold A; Thompson AJ; Miller DH; Giovannoni G Mult Scler; 2010 Sep; 16(9):1066-72. PubMed ID: 20639271 [TBL] [Abstract][Full Text] [Related]
43. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Barkhof F; van Waesberghe JH; Filippi M; Yousry T; Miller DH; Hahn D; Thompson AJ; Kappos L; Brex P; Pozzilli C; Polman CH; Brain; 2001 Jul; 124(Pt 7):1396-402. PubMed ID: 11408334 [TBL] [Abstract][Full Text] [Related]
44. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Inglese M; van Waesberghe JH; Rovaris M; Beckmann K; Barkhof F; Hahn D; Kappos L; Miller DH; Polman C; Pozzilli C; Thompson AJ; Yousry TA; Wagner K; Comi G; Filippi M Neurology; 2003 Mar; 60(5):853-60. PubMed ID: 12629246 [TBL] [Abstract][Full Text] [Related]
45. Effect of interferon-β1α therapy on multiple sclerosis based on gadolinium-enhancing or active T2 magnetic resonance imaging outcomes: a meta-analysis. Lu Y; Zhao J; Zhan Q Neurol Res; 2016 Oct; 38(10):909-15. PubMed ID: 27553873 [TBL] [Abstract][Full Text] [Related]
53. Primary progressive multiple sclerosis : current and future treatment options. Leary SM; Thompson AJ CNS Drugs; 2005; 19(5):369-76. PubMed ID: 15907149 [TBL] [Abstract][Full Text] [Related]
54. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. Koch MW; Mostert J; Repovic P; Bowen JD; Uitdehaag B; Cutter G Neurology; 2021 Jan; 96(1):e111-e120. PubMed ID: 33106389 [TBL] [Abstract][Full Text] [Related]
55. [Autoimmune functional disorders of the thyroid during interferon-beta-1b treatment in patients with multiple sclerosis. Case report and literature review]. Lange-Asschenfeldt C; Boor S; Kahaly GJ; Thömke F Nervenarzt; 2004 Jun; 75(6):589-94. PubMed ID: 15257382 [TBL] [Abstract][Full Text] [Related]
56. MRI and assessment of treatment in multiple sclerosis. Miller DH; Thompson AJ; Kappos L Brain; 2001 May; 124(Pt 5):1052-3. PubMed ID: 11335707 [No Abstract] [Full Text] [Related]
57. [A study of the efficacy of infibeta in patients with multiple sclerosis based on NEDA-3]. Kotov SV; Kudlay DA; Lizhdvoy VY; Stashuk GA; Magomedova SB Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):107-115. PubMed ID: 31156249 [TBL] [Abstract][Full Text] [Related]
58. Overview of London trial of intramuscular interferon-beta Ia in primary-progressive multiple sclerosis. Miller DH; Leary SM; Thompson AJ Mult Scler; 2004 Jun; 10 Suppl 1():S56-7. PubMed ID: 15218810 [TBL] [Abstract][Full Text] [Related]
59. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. Patti F; Cataldi ML; Nicoletti F; Reggio E; Nicoletti A; Reggio A J Neurol Neurosurg Psychiatry; 2001 Sep; 71(3):404-7. PubMed ID: 11511721 [TBL] [Abstract][Full Text] [Related]